Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
The first new non-opioid for severe acute pain has been on the market for a few months. But it's a lot more expensive than opioids, and many people can't get it because of spotty insurance coverage.
-
Advisers to the Centers for Disease Control and Prevention recommended against flu shots containing the ingredient thimerosal. Why is the additive, safely used since the 1930s, being questioned again? -
Thimerosal has been a target of groups that question vaccine safety. What vaccines still contain the mercury compound, and what would happen if the recommendations against its use become official?
-
While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, others are continuing and pushing regulatory boundaries. -
Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of the drugs. But some of those business are trying to find ways to continue.
-
In the shadow of President Trump's efforts to lower drug prices, the Medicare drug price negotiation process that began in the Biden administration continues. -
The singer canceled his summer tour dates and revealed he has a brain condition called normal pressure hydrocephalus. It's treatable but tricky to diagnose, doctors say. -
President Trump's latest executive order on drug prices aims to lower them by bringing them into line with what other developed countries pay. Experts caution that this is no small task.
-
President Trump wants to lower drug prices in the U.S. by tying them to the prices paid in other developed countries. The pharmaceutical industry has long opposed the approach. -
House Rep. Gerry Connolly is pushing CDC leadership to explain why the personnel who handle FOIA requests lost their jobs, noting that that the public has a right to access federal records.
